Herbert Hurwitz
PathologyOncologyBevacizumabColorectal cancerMedicine
What is this?
Publications 411
#1Xiaoju Max Ma (Hoffmann-La Roche)
#2Johanna C. Bendell (Sarah Cannon Research Institute)H-Index: 38
Last. Nicolas Sommer (Genentech)H-Index: 5
view all 14 authors...
Purpose: We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy. Experimental Design: STEAM was a randomized, phase II trial investigating efficacy of bevacizumab (BEV) plus 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI), administered concurrently or sequentially, versus FOLFOX-BEV in first-line mCRC. Evaluation of biomarke...
#1Josep GarciaH-Index: 8
#2Herbert HurwitzH-Index: 60
Last. Olivier ChinotH-Index: 43
view all 7 authors...
Abstract When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical practice more than 15 years ago, it was one of the first targeted therapies and the first approved angiogenesis inhibitor. Marking the beginning for a new line of anti-cancer treatments, it remains the most extensively characterized anti-angiogenetic treatment. Initially approved for treatment of metastatic colorectal cancer in combination with chemotherapy, indications of bevacizumab now include metas...
#1Johanna C. BendellH-Index: 38
#1Johanna C. BendellH-Index: 25
Last. Herbert Hurwitz (Durham University)H-Index: 60
view all 26 authors...
BACKGROUND: Bevacizumab, a VEGF-A inhibitor, in combination with chemotherapy, has proven to increase progression-free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin-2 (Ang-2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF-A and Ang-2, suggesting that the dual VEGF-A and Ang-2 blocker vanucizumab (RO5520985 or R...
#2Guilherme S. Lopes (Mayo Clinic)
Last. Carsten Bokemeyer (UHH: University of Hamburg)H-Index: 40
view all 15 authors...
89Background: Monitoring of adverse events (AE) is crucial in clinical trials. Maximum grade per patient (pt) is commonly used but better metrics are needed to aid describing and comparing AE profi...
#1Angeles Alvarez Secord (Duke University)H-Index: 43
#2Kirsten Burdett (NU: Northwestern University)
Last. Andrew B. Nixon (Duke University)H-Index: 22
view all 21 authors...
Purpose: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free survival (PFS), but no overall survival (OS) benefit with bevacizumab. Blood samples were collected for biomarker analyses. Experimental Design: Plasma samples were analyzed via multiplex ELISA technolo...
1 CitationsSource
#1John H. Strickler (Duke University)H-Index: 12
#2Christel Rushing (Duke University)H-Index: 8
Last. Herbert Hurwitz (Genentech)H-Index: 60
view all 20 authors...
Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) for the combination of capecitabine and ziv-aflibercept, and then we evaluated the efficacy of the combination in patients with chemotherapy refractory metastatic CRC. All patients were required to have a Karnofsky Performance Status > 70% and adequat...
#1Niharika B. Mettu (Duke University)H-Index: 3
#2E. Twohy (Mayo Clinic)
Last. Tanios Bekaii-Saab (Mayo Clinic)H-Index: 37
view all 19 authors...
Abstract Background The benefit of immune checkpoint blockade in mCRC is currently limited to mismatch repair (MMR) deficient tumours. Increasing evidence suggests that the vascular endothelial growth factor (VEGF) pathway plays a role in cancer immune evasion. Co-targeting the PD-1/PD-L1 and VEGF axes may result in clinical activity in mCRC. Methods 133 patients (pts) were randomized 2:1 to receive C/B/P (Arm A) or C/B/A (Arm B), stratifying by ECOG and RAS. Pts had progressed on 5-FU, oxalipla...
#1Tomasz Burzykowski (UCL: Université catholique de Louvain)H-Index: 35
#2Elisabeth Coart (UCL: Université catholique de Louvain)H-Index: 3
Last. Marc Buyse (University of Hasselt)H-Index: 71
view all 27 authors...
Importance Tumor measurements can be used to estimate time to nadir and depth of nadir as potential surrogates for overall survival (OS). Objective To assess time to nadir and depth of nadir as surrogates for OS in metastatic colorectal cancer. Design, Setting, and Participants Pooled analysis of 20 randomized clinical trials within the Aide et Recherche en Cancerologie Digestive database, which contains academic and industry-sponsored trials, was conducted. Three sets of comparisons were perfor...
#1Jeffrey Melson Clarke (Duke University)H-Index: 9
#2Gerard C. Blobe (Duke University)H-Index: 46
Last. Herbert Hurwitz (Genentech)H-Index: 60
view all 17 authors...
Purpose This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory metastatic colorectal cancer.
#1Federico Innocenti (UNC: University of North Carolina at Chapel Hill)H-Index: 43
#2Chen Jiang (Duke University)H-Index: 15
Last. Kouros Owzar (Duke University)H-Index: 29
view all 17 authors...
ObjectivesOne of the standard of care regimens for advanced pancreatic cancer is gemcitabine-based chemotherapy. The efficacy of gemcitabine is limited by dose-limiting hematologic toxicities especially neutropenia. Uncovering the variability of these toxicities attributed to germline DNA variation